List of Camcevi Kit drug patents

Camcevi Kit is owned by Accord.

Camcevi Kit contains Leuprolide Mesylate.

Camcevi Kit has a total of 3 drug patents out of which 0 drug patents have expired.

Camcevi Kit was authorised for market use on 25 May, 2021.

Camcevi Kit is available in emulsion;subcutaneous dosage forms.

The generics of Camcevi Kit are possible to be released after 16 January, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646572 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US9572857 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US9744207 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage

CAMCEVI KIT family patents

7

United States

2

Korea, Republic of

1

Taiwan, Province of China

1

Slovenia

1

Hong Kong

1

Australia

1

Russia

1

Denmark

1

Canada

1

Mexico

1

Spain

1

Japan

1

China

1

Brazil

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic